A5015446939- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- Cutaneous Melanoma Detection and Management
- Chronic Lymphocytic Leukemia Research
- Nonmelanoma Skin Cancer Studies
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Oral Health Pathology and Treatment
- Computational Drug Discovery Methods
- Immunotherapy and Immune Responses
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Polyomavirus and related diseases
- Chronic Myeloid Leukemia Treatments
- Cancer and Skin Lesions
- Systemic Lupus Erythematosus Research
- COVID-19 and healthcare impacts
- Full-Duplex Wireless Communications
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Dermatology and Skin Diseases
- Drug-Induced Ocular Toxicity
- Antenna Design and Analysis
- COVID-19 Clinical Research Studies
Université Paris Cité
2018-2024
Hôpital Saint-Louis
2017-2024
Assistance Publique – Hôpitaux de Paris
2018-2024
Délégation Paris 7
2019-2024
Inserm
2019-2024
Institut Gustave Roussy
2024
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2021
Centre d'Investigation Clinique de Nantes
2021
HIPI - Immunologie humaine, physiopathologie et immunithérapie
2018-2020
GTx (United States)
2020
This study assessed the prognostic value of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic solid tumors. Clinical and biological data for tumors treated an oncology outpatient department prospectively followed by a call center (PROCHE program) between January 2008 December 2011 were analyzed. All NLR within 28 days before first cycle first-line chemotherapy included (cohort 1). To assess influence line on value, from later lines also analyzed 2). Adjusted...
Immune checkpoint inhibitors for melanoma improve adaptive T cell immunity during COVID-19 without exacerbating inflammation.
Immune-checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen-4 and programmed cell death ligand-1) are associated with several immune-related neurological disorders. Cases of meningitis related to ICIs poorly described in literature probably underestimated. Several guidelines available for the acute management these adverse events, but safety resuming patients remains unclear. We conducted a retrospective case series that occurred between October 1 2015 31 2019 two...
Sonidegib, a hedgehog pathway inhibitor, is indicated for treatment of locally advanced basal cell carcinoma, based on the results BOLT study. However, to date, no real-world study sonidegib has been reported. An observational, retrospective, single-centre (PaSoS study) was conducted. The primary objective evaluate efficacy carcinoma in setting. Secondary objectives included modalities use, tolerability, tumour evolution, and management after discontinuation. A total 21 patients treated with...
KIT is a bona fide oncogene in subset of melanoma and, ex vivo, inhibitors are very efficient at killing KIT-mutant cell lines. However, tumors tend to show de novo resistance most cases and limited duration response when achieved. We performed pharmacodynamic studies on patients with KIT-mutated treated nilotinib, which suggested that the FGF2 axis may be mechanism this melanoma. Using several lines, dependent oncogenic KIT, we showed although inhibition markedly decreased viability lines...
Few data are available on patients with leptomeningeal disease (LM) from melanoma treated new systemic therapies. To gain a better understanding of patients, characteristics, and therapeutic interventions in LM the era treatment. Clinical treatments, survival diagnosed LM, isolated or associated brain metastases, were collected. The Cox regression model assessed influence patient characteristics survival. Monocentric, retrospective, real-life cohort melanoma. All followed up at Saint-Louis...
Dear Editor, Brain metastases occur in the progression of metastatic melanoma up to 44% cases.1 Despite evidence clinical benefit combined immunotherapies on brain metastases,2 more than 50% patients will have progression, challenging daily practice oncology. Molecular markers predictive risk remain largely be identified.3 In our study, we performed transcriptomic analyses laser-microdissected tumor cells from lymph nodes with melanoma, identify biomarkers associated occurrence over a median...
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer that can metastasize rapidly. In patients with metastatic MCC (mMCC), brain metastases are uncommon but associated poor prognosis; furthermore, there limited published literature regarding treatment of these patients, no specific regimens currently recommended by guidelines. Avelumab, an anti–programmed death ligand 1 monoclonal antibody, was the first approved for mMCC. Here, we present 4 cases mMCC treated avelumab. Patient...
Abstract BACKGROUND Immune checkpoint inhibitors (ICIs) are associated with a wide range of neurotoxicities. Several types neuropathies have been to immune (ICIs), from length-dependent sensory radiculoneuropathies similar Guillain-Barré syndromes, an overall incidence estimated be between 0.1-1.2% patients. Guidelines recommend prompt ICI discontinuation and the INTRODUCTION steroids depending on severity adverse event. However, usage IVIG or plasmapheresis (alternatively in addition...